ArticleCell communication and signaling : CCS2023
Extracellular vesicles of the probiotic bacteria E. coli O83 activate innate immunity and prevent allergy in mice.
Article in Cell communication and signaling : CCS, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 19 citations in OpenAlex.
- Probiotic extracellular vesicles reprogram macrophage immunometabolism: From gut crosstalk to host health.Gut microbes · 2026Review
- Gram-Positive and Gram-Negative Probiotic Extracellular Vesicles: Mechanisms of Immune Modulation and Therapeutic Opportunities in Atopic Dermatitis.Clinical reviews in allergy & immunology · 2026Review
- Selective Packaging of miR-22 and miR-29 Orthologues into Extracellular Vesicles of the Porcine Whipworm Trichuris Suis.Journal of extracellular vesicles · 2026Article
- Postbiotics as Multifunctional Bioactives: Mechanistic Insights and Translational Applications in Host Physiology and Microbial Ecosystem Modulation.Microorganisms · 2026Review
- Gnotobiotic mouse models as tools for dissecting the role of the microbiota in allergy: contributions from the laboratory of gnotobiology in Nový Hrádek.Folia microbiologica · 2026Review
- Engineered Escherichia coli as a microbial cell factory for intracellular protein delivery: strains, vectors, mechanisms, and therapeutic applications.Microbial cell factories · 2026Review
- Microbial extracellular vesicles in the lung: friends in health, agents in disease.Extracellular vesicles and circulating nucleic acids · 2026Review
- The lung microbiome and asthma: from inflammatory phenotype differentiation to microbe-based immunomodulatory strategies.Frontiers in immunology · 2026Review
- Immunomodulatory properties of probiotic extracellular vesicles- do they have the potential to fill the gap in therapeutic strategies for allergies?Cell communication and signaling : CCS · 2025Review
- The Role of Oral and Gut Microbiota in Bone Health: Insights from Bacterial Extracellular Vesicles.Microorganisms · 2025Review
- Gut microbiome impact on childhood allergic rhinitis and house dust mite IgE responses.Pediatric research · 2025Article
- On the road: extracellular vesicles in intercellular communication.Cell communication and signaling : CCS · 2025Article
- Probiotic-derived extracellular vesicles: the next breakthrough in postbiotics for rheumatoid arthritis.Frontiers in immunology · 2025Review
- Probiotic-derived extracellular vesicles: a novel weapon against viral infections.Bioscience of microbiota, food and health · 2025Review
- A critical evaluation of methodological and mechanistic insights on probiotic-derived extracellular vesicles.Frontiers in nutrition · 2025Review
- Respiratory Flora Intervention: A New Strategy for the Prevention and Treatment of Occupationally Related Respiratory Allergy in Healthcare Workers.Microorganisms · 2024Review
- Article
- Bacterial extracellular vesicles as intranasal postbiotics: Detailed characterization and interaction with airway cells.Journal of extracellular vesicles · 2024Article
- Correction: Extracellular vesicles of the probiotic bacteria E. coli O83 activate innate immunity and prevent allergy in mice.Cell communication and signaling : CCS · 2023Article
- Review
Corrections and comments
- Erratum issued
Authors and funding
21 authors at 9 institutions in 4 countries.
Funding
Abstract
backgroundE. coli O83 (Colinfant Newborn) is a Gram-negative (G-) probiotic bacterium used in the clinic. When administered orally, it reduces allergic sensitisation but not allergic asthma. Intranasal administration offers a non-invasive and convenient delivery method. This route bypasses the gastrointestinal tract and provides direct access to the airways, which are the target of asthma prevention. G- bacteria such as E. coli O83 release outer membrane vesicles (OMVs) to communicate with the environment. Here we investigate whether intranasally administered E. coli O83 OMVs (EcO83-OMVs) can reduce allergic airway inflammation in mice.
methodsEcO83-OMVs were isolated by ultracentrifugation and characterised their number, morphology (shape and size), composition (proteins and lipopolysaccharide; LPS), recognition by innate receptors (using transfected HEK293 cells) and immunomodulatory potential (in naïve splenocytes and bone marrow-derived dendritic cells; BMDCs). Their allergy-preventive effect was investigated in a mouse model of ovalbumin-induced allergic airway inflammation.
resultsEcO83-OMVs are spherical nanoparticles with a size of about 110 nm. They contain LPS and protein cargo. We identified a total of 1120 proteins, 136 of which were enriched in OMVs compared to parent bacteria. Proteins from the flagellum dominated. OMVs activated the pattern recognition receptors TLR2/4/5 as well as NOD1 and NOD2. EcO83-OMVs induced the production of pro- and anti-inflammatory cytokines in splenocytes and BMDCs. Intranasal administration of EcO83-OMVs inhibited airway hyperresponsiveness, and decreased airway eosinophilia, Th2 cytokine production and mucus secretion.
conclusionsWe demonstrate for the first time that intranasally administered OMVs from probiotic G- bacteria have an anti-allergic effect. Our study highlights the advantages of OMVs as a safe platform for the prophylactic treatment of allergy. Video Abstract.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.